Have a question about INOmax® (nitric oxide) gas, for inhalation?

Request information

Let us know how we can help by filling out the form below and we’ll address your request. You can also email CritCare-INFO@mallinckrodt.com.

Please do not use this form to report adverse events. Adverse event reporting should be directed to our Customer Care Department at 1-877-KNOW-INO (1-877-566-9466).

*Required fields.
Select one

Please Select One

ENTER YOUR INFORMATION

Select prefix

Please select prefix

Select role

Please select role.

Please select one.

ENTER INFORMATION FOR YOUR FACILITY

AL

Please select state.

By selecting submit, I agree to these Terms of Use and Privacy Policy. I also hereby consent to Mallinckrodt Pharmaceuticals (“Mallinckrodt”), through its third-party designees or directly, using my information to send me communications regarding Mallinckrodt-sponsored information on products and educational programs that may be of interest to me. I understand that Mallinckrodt and its designees will not sell, transfer to, or otherwise share my information with any third party except as set forth in Mallinckrodt’s Privacy Policy located at www.mallinckrodt.com/privacy-policy. At any time, I can stop receiving communications from INOmax.com by clicking the “unsubscribe” link at the bottom of future emails.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.

Live help is available 24/7/365

Call 877-566-9466

Quick Links

INOmax DSIR® Plus Virtual Training Simulator Resource Library FLEXtraNet® Log-in INOmax DSIR® Plus Operation Manual INOmax DSIR® Plus MRI Operation Manual

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

This website may identify third-party organizations and provide links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

© 2024 Mallinckrodt. All rights reserved. US-2400124 03/24

By viewing this site you agree to our Terms of Use. The product information provided in this site is intended only for residents of the United States. The product discussed herein may have different product labeling in different countries.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.